Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

793.26
-14.3900-1.78%
Pre-market: 831.7138.45+4.85%06:22 EDT
Volume:526.91K
Turnover:419.07M
Market Cap:81.67B
PE:19.62
High:806.14
Open:794.36
Low:792.00
Close:807.65
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.88
T/O Rate:0.53%
Dividend:3.64
Dividend Rate:0.46%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.58
PE(LYR):19.12

Loading ...

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

TIPRANKS
·
Jun 30

Eli Lilly, Regeneron Among First Companies Selected for FDA Initiative to Speed Review of New Manufacturing Facilities - CNBC

THOMSON REUTERS
·
Jun 30

Healthcare Stocks Have Become a Haven for Investors Ditching Tech

Dow Jones
·
Jun 27

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 27

How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment

Simply Wall St.
·
Jun 27

Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call

Reuters
·
Jun 26

Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways

TIPRANKS
·
Jun 26

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion

Dow Jones
·
Jun 22

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Dow Jones
·
Jun 22

Regeneron says FDA accepts cemdisiran gMG filing for priority review

Reuters
·
Jun 22

Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

GlobeNewswire
·
Jun 22

AbbVie would gain an experimental eczema drug by buying biotech: report

Dow Jones
·
Jun 21

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 18

Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting

Reuters
·
Jun 18

Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations

Simply Wall St.
·
Jun 13